Skip to main content
logo
Samsung Biologics Co.,Ltd. (KRX:207940)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,780,000
-11,000 (-0.61%)
Last updated: Jan 29, 2026, 2:10 PM KST

Samsung Biologics Revenue

In the year 2025, Samsung Biologics had annual revenue of 4.56T KRW with 0.21% growth. Samsung Biologics had revenue of 1.29T in the quarter ending December 31, 2025, with 2.35% growth.

Revenue
4.56T
Revenue Growth
+0.21%
P/S Ratio
18.19
Revenue / Employee
955.35M
Employees
4,770
Market Cap
82.91T

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20254.56T9.68B0.21%
Dec 31, 20244.55T852.73B23.08%
Dec 31, 20233.69T693.29B23.10%
Dec 31, 20223.00T1.43T91.41%
Dec 31, 20211.57T403.23B34.62%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
Celltrion3.90T
SK Biopharmaceuticals675.41B
SK bioscience624.03B
PharmaResearch496.03B
Hugel404.19B
ALTEOGEN202.18B
LigaChem Biosciences159.27B
HLB Co., Ltd.80.73B
Revenue Rankings

Samsung Biologics News

More News